Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.00 -
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 64.06 -20.89 -22.10
Last Trade Time Trade Type Trade Size Trade Price Currency
- 0 GBX

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Investors    Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date Time Title Posts
03/12/202019:36Feck off the_doctor10,999
03/12/202008:27Oxford Biomedica1,653
30/11/202000:00Truth Vs. Deception49
23/11/202008:59OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD72,943
06/11/202010:41Oxford Biomedica Bulls Only Thread31,098

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:35:12863.007896,809.07O
17:05:33860.352231,918.59O
17:02:46854.0443367.24O
16:59:52853.0288750.66O
16:35:01863.0027,329235,849.27UT
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

DateSubject
03/12/2020
08:20
Oxford Biomedica Daily Update: Oxford Biomedica Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 865p.
Oxford Biomedica Plc has a 4 week average price of 785p and a 12 week average price of 775p.
The 1 year high share price is 899p while the 1 year low share price is currently 366p.
There are currently 82,223,225 shares in issue and the average daily traded volume is 204,182 shares. The market capitalisation of Oxford Biomedica Plc is £709,586,431.75.
03/12/2020
08:03
fp optimist: But Bountyhunter, so far all on track and quite rightly OXB share price should stay firm until awaiting new information. In a rational world, surely Pfizer are justified in getting first approval. Pfizer were first with spectacularly good results; their solution is expensive, but it can be delivered to the most sensitive and important area - namely hospitals. I hope AstraZeneca/Oxford will follow soon with MHRA approval, before the end of the year, it especially using its current EU designated criteria and approach.
28/11/2020
19:31
pezza51053: Can’t wait for next week - I think Boris will run with either Pfizer or Oxb/AST but the Pfiser allocation will run out quickly. If the Oxb is approved it will run away with it - save the world and OXB will be “on the map” and ready to showcase their pipeline of innovation Kneck on the block; £1.50 to £2 jump prior to Xmas £20 on T/O in either 2021 or 2022 If this doesn’t come true - I will stick to house builders
23/11/2020
09:21
pharmaboy3: Official rns from oxbOxford Biomedica PLC - OXB notes AZD1222 met primary efficacy endpoint #OXB @OxfordBioMedic HTTps://www.voxmarkets.co.uk/rns/announcement/203e59d3-910d-49d4-9eb8-bcce4bf85cb6 #voxmarkets
20/11/2020
10:13
dominiccummings: OR, OXB's share price has held up well through a period when thousands of companies fail and share prices are slashed. Continued production and shipping whilst coping with the issues concerned with the pandemic including cleaning, spacing, lockdowns and so on. I suspect that Axovant issue has more to do with change of plans than OXB production. As to IT, it is well known that OXB, and only them, are inextricably intertwined with Microsoft developing software that accelerates drug development...... who would be a better partner? Limited objectives? cosy life-style company? Nonsense on stilts!
20/11/2020
00:26
fp optimist: Today's share trading illustrates what some of us have felt for some time. Phase 2 publication appears to have been good news for the AZ-Oxford led consortium (AZN up £10 per share), but not for Oxford Bio, which trickled 3p down. I had assumed that Oxford Bio were supposed to be one of the stars in the AZ / Oxford University consortium. After some year's experience, they were supposed to be ahead in commercial production. But this seems to have dropped out of the publicity arena. I would be surprised, if OXB is genuinely interested in meeting the challenges of growth. Left to his own devices, JD appears to project a cosy life-style company. Conservative treasury strategy (low gearing / no borrowing); and conservative financial accounts (no profits; exceptionally poor Gross Margins; no IPR and intangibles). I was fascinated by Raposa' July presentation on Bioprocessing Informatics (https://www.youtube.com/watch?v=wLprtK_K0vA). Very university style - bright kid hacking it; devising experiments; with potentially too limited scope and objectives and limited software; certainly showing a lack of strategic perspective resulting from lack of boardroom guidance and interest? No wonder Axovant blames its slow-down on production problems with Oxford Biomedica. However, good news on OXB's current valuation. The last Berenberg analysis more or less agreed with current market price: it only valued future licence income. Any production margin would be a bonus. Does this mean OXB is still undervalued? Any comments?
18/11/2020
22:44
the lockkeeper: Pfizer share price now around pre announcement price,not that it moved a great deal anyway, any thoughts?Hoping OXB has a good run upwards when AZN trials finish.I realise the logistics of a very cold supply chain may have an effect but particularly in developed countries that's not a massive problem.
06/10/2020
22:21
harry s truman: I'm sure quite a lot of people bought AXGT over the last few days in anticipation of good news on the second cohort and details of recruitment for the sham stage. I say this with some confidence as I am one of those people who bought a few shares thinking it was a sure thing (hence the other thread). When I saw shares changing hands at over 6 dollars in pre-market this morning I nearly awarded myself several gold stars for brilliance. Unfortunately it was only minutes later that they released data on 2 patients and said that they will be recruiting another cohort before sham. They will be as optimistic with timescales as they can be, but the reality of this will be a year delay to their program. The share price will pay that price and I will eat a loss. Fortunately I can afford it and will put it down to experience. Not my greatest day. With my OXB hat on, it's still a milestone for moving to cohort 3 (around 15m USD I guess) and a bag full of money (another 1m USD at least) for making the bioreactor batch for the sham trial.
06/10/2020
17:26
gareth jones: The share price is resilient against upward moves it seems, it doesn’t seem to mind down turns. The dam analogy hopefully is appropriate. Once again I think many LTH’s believe we have never been in a better position to capitalize on our true potential as a company. Brokers appear to agree there is upgrade from here. Perhaps Axovant presentation tonight may enthuse a few on the other side of the pond.Two positive RNS announcements from OXB in one day, one backed by HMG to treat potentially a pandemic and one a Parkinsons trial result and up 6p!!! Come on OXB.
06/10/2020
10:59
marcusl2: in addition to existing forecasts for Kymriah (across multiple indications) and a second CAR-T (which we assume is for multiple myeloma). Follicular lymphoma is the second most common form of non-Hodgkin lymphoma (NHL), and represents ~22% of NHL cases. MCM998, a BCMA-targeting CAR-T for use in patients with multiple myeloma (NOVN is developing a BCMA and CD19 CAR-T combination). Following the expansion to the NOVN collaboration, we have added a third CAR-T programme (undisclosed but we assume CD22 for adult ALL). We forecast that OXB will sell vector batches to NOVN for $1.5m per batch, with peak gross margins of 30%. We highlight that further collaboration on CAR-T assets between OXB and NOVN is possible as NOVN continues to invest heavily in its CGT capabilities. We assume a $7m (c £5.2m) reservation fee will be spread across the five-year contract with no financial impact until 2021 under the expanded collaboration agreement. Juno CAR-T or TCR-T assets in preclinical and clinical development and may include one of the CD22, WT1, L1CAM and MUC16 programmes) over multiple potential indications (discussed below). Beam $5m upfront. Beam’s base editing technology has the potential to enable a new class of genetic medicines where a specific single base in the genome is corrected (point mutations or genetic error of a single base make up ~58% of all known errors associated with disease). Beam’s approach targets a single base in a genome without making a double-stranded break in the DNA, unlike established gene editing technologies (eg CRISPR). Beam is currently developing a diversified portfolio of 12 base editing programmes against distinct targets and is evaluating optimal clinically validated delivery approaches for each programme. While OXB has not disclosed the exact details of the project it is working on, we believe the relevant product appears to be the engineered allogeneic (or off-the-shelf) CAR-T products, via multiplex editing of T-cells from healthy donors. These ex vivo gene therapies benefit from the use of LVV to deliver a target gene (presumably for the CAR) as they integrate into the host cell genome (as appose to AAV) so the target gene is maintained when the cells are expanded (cultured to divide and multiply), prior to administration. In vivo gene therapies however, could utilise either LVV or AAV vectors. AZ. This valuable knowledge exchange will stand OXB in good stead if it was to pursue the manufacturing of adenoviral vectors in the future. Bioverativ’s gene therapies are in preclinical trials, and Sanofi has recently communicated it expects both assets to move into the clinic in 2022. Our model assumes these gene therapies could launch in 2026 (from 2025), with accelerated approval after completing Phase II trials. We believe the focus on LVV may prove an advantage as durability of effect of gene therapies in haemophilia has been in the spotlight, given cost per treatment. AAV-This clearly raises durability questions around whether the Factor VIII activity may drop to a point where it no longer provides protection from bleeds, a serious concern for a treatment that could cost $2–3m. Bioverativ and OXB could gain significant market share if they are able to improve on the AAV products in development. Although cell turnover in the liver is slow, LVVs may have a potential advantage as they integrate into the host cell genome and the target gene is therefore maintained as cells divide, potentially increasing durability. HTTps://www.edisongroup.com/publication/vector-innovation-key-to-cell-and-gene-evolution/27906
06/10/2020
10:16
harry s truman: I seem to remember £25 from somewhere bunlop, but I guess they up their notional value + bid premium figure each time a new deal / prospect is announced by OXB. The OXB share price always has an odd relationship with news. The more we have of it the less reaction there seems to be. I've been surprised how unaffected we have been by the vaccine tie-up as we are effectively the key supplier to the lead candidate. You would never guess this by the price. At some point there will be a revaluation. Some new news or action will break the dam and then we end up at a different level.
Oxford Biomedica share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OXB
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201203 19:43:15